For the year ending 2025-12-31, TBPH made $107,464K in revenue. $105,895K in net income. Net profit margin of 98.54%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 107,464 | 64,381 | ||
| Research and development | 37,414 | 37,643 | ||
| Impairment of long-lived assets (non-cash) | - | 4,513 | ||
| Selling, general and administrative | 73,652 | 69,174 | ||
| Total expenses | 111,066 | 111,330 | ||
| Loss from operations | -3,602 | -46,949 | ||
| Net gain on realized contingent milestone and royalty assets | 75,137 | - | ||
| Trelegy milestone income | 50,000 | - | ||
| Interest expense (non-cash) | 2,461 | 2,546 | ||
| Interest and other income, net | 10,173 | 4,881 | ||
| Income (loss) before income taxes | 129,247 | -44,614 | ||
| Provision for income tax benefit (expense) | 23,352 | 11,804 | ||
| Net income (loss) | 105,895 | -56,418 | ||
| Basic EPS | 2.1 | -1.15 | ||
| Diluted EPS | 2.06 | -1.15 | ||
| Basic Average Shares | 50,317,000 | 48,847,000 | ||
| Diluted Average Shares | 51,507,000 | 48,847,000 | ||
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)